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ABSTRACT 
 
MARY K. LA: Predicting Adverse Drug Effects from Literature Assertions that Link 
Drugs to Targets and Targets to Effects 
(Under the direction of Alexander Tropsha) 
Adverse drug effects (ADEs) are a major reason for drug candidate failure in 
clinical trials; thus, it is critical to predict possible ADEs in the early stages of drug 
discovery. In this study, cheminformatics, bioinformatics, and data mining approaches 
were employed to integrate and analyze publicly-available pharmacological and clinical 
data with the goal of inferring novel associations between drugs, targets, and ADEs. A 
new database was created that integrated experimental drug-target binding data and 
known associations between drugs (7448 unique instances), targets (1280), and ADEs 
(4492) expressed as assertions found in the literature. Unreported associations between 
drugs, targets, and ADEs were inferred, and inferences were prioritized as testable 
hypotheses. As a proof of concept, an association was identified between paroxetine and 
thrombocytopenic purpura using a focused subset of ~47K top-ranked inferences 
published prior to the first reports confirming this association in 2013. 
Given the increasing costs of bringing new drug entities to market, there is a 
strong need for cost-effective methods of identifying potential adverse effects of a drug 
candidate early on in the development process. The workflow presented here, based on 
free-access databases and an association-based inference scheme, has provided chemical-
ADE inferences that have been validated post-hoc in literature case reports. With 
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refinement of prioritization schemes for the generated chemical-ADE inferences, this 
workflow may provide an effective computational method for the early detection of drug 
candidate ADEs.  
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1. BACKGROUND AND RESEARCH GOALS 
 
 Adverse drug effects (ADEs) are non-preventable, negative pathological or 
physiological consequences resulting from the use of a drug product that may or may not 
manifest as adverse drug reactions (ADRs)
1
. Between 1999-2006, annual rates of ADR-
related mortalities were as high as 0.12/100,000 cases in the United States
2
. Because 
ADRs are notoriously underreported, the annual morbidity and mortality rates may 
actually be much higher
2
. ADRs significantly increase the actual length of hospital stay 
and overall cost of hospitalization
3
, and contribute to the annual $5.6 billion in adverse 
drug event costs according to the US Agency for Healthcare Research and Quality
4
 . 
Anticipating and managing ADEs have been critical areas of research for decades. 
Indeed, the structure of the Food and Drug Administration’s (FDA) new drug approval 
process allows for multiple opportunities to identify ADEs before the drug candidate 
reaches the market. Furthermore, post-marketing surveillance may discover additional 
ADEs, especially ones that occur infrequently. Nevertheless, rare but severe ADEs have 
caused several drugs to be withdrawn from the market, e.g., the non-steroidal anti-
inflammatory drug pirprofen in 1990 for fatal hepatotoxicity, the antihistamine 
terfenadine in 1998 for prolonged QTc, and the HMG-coA reductase inhibitor cerivastatin 
in 2001 for increased rhabdomyolysis risk, etc.
5
  
Informatics techniques have been pursued to study ADEs. For instance, Don 
Swanson developed a text-mining inference paradigm
6
 using published literature: if an 
article associated chemical entity (A) with a physiological process (B), and if another 
article associated the same physiological process (B) with an effect (C), then an 
2 
 
association between chemical (A) and effect (C) could be inferred (Figure 1.1). Swanson 
used this ABC paradigm to correctly predict that magnesium supplementation would 
reduce the occurrence of migraines, an inference that has been subsequently 
experimentally validated
7
.  
Figure 1.1 Swanson’s ABC paradigm. This model frames the association (edge) 
between chemical, target, and ADE (vertices). The triangle at the bottom shows one 
inference presented in Swanson’s original paper on the ABC paradigm6. A deficit of 
magnesium contributed to vasospasm, which is a molecular mechanism for migraine. 
Therefore, it was inferred that a deficit of magnesium could lead to migraine. This was 
experimentally confirmed after the inference was made
7
. 
 
The publicly-accessible FDA Adverse Event Reporting System (FAERS) database
8 is a 
critical tool for identifying rare ADEs in post-marketing surveillance. There have been 
efforts to mine FAERS for drug interaction adverse events
9
. Electronic health records and 
Medline have also served as knowledge bases for other data mining investigations
10
. A 
detailed review of available data sources for systems pharmacology is available from Bai 
et al.
11 
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In silico strategies to predict drugs’ off- and on-target interactions as well as 
associated adverse and therapeutic effects have been actively pursued (Table 1.1).  
Table 1.1 Computational studies linking drugs, targets, and side-effects/diseases. 
Study 
Chemicals 
(C) 
Targets 
(T) 
Effects (E) / 
Indications (D) 
Goal Method
a
 
Yang et al
12
 303 - 584/145 C-D by C-E ML 
Yamanishi et al
13
 658 1,368 969 
C-E by C, 
C-T 
KM, CCA 
Cheng et al
14
 953 (1,200) 13,255 C-E 
DB, 
Inference 
Cami et al
15
 809 - 852 C-E Network 
Chen et al
16
 157 1,683 - C-T Network 
Campillos et al
17
 746 (<1,000) 1,182 C-T by C-E Similarity 
Lounkine et al
18
 656 73 (339) -/317 
C-T(D) by 
C 
Similarity 
Oprea et al
19
 988 (1,750) 174/? C-D DB, PCA 
Davis et al
20
 5,562 9,167 2,697 C-T-E DB 
King et al
21
 6,406 20,898 3,999 C-T-E Inference 
Simon et al
22
 1,177 149 -/177 C-D by C-T CCA, LDA 
Wang et al
23
 593 (<4,323) 1,450/313 C-D 
KM, 
Similarity 
Wallach et al
24
 730 830 506 
C-E by 
pathway  
Inference 
Mathur et al
25
 948 >1,480 -/581 
C-D by 
pathway 
Inference 
a 
DB – database creation, ML – machine learning methods (e.g., SVM), CCA – canonical 
correlation analysis, PCA – principal component analysis, KM – Kernel methods. 
 
A substantial number of those computational studies are dedicated to drug 
repurposing (Table 1.1, “C-T” or “C-D” in the “Goal” column). For example, Campillos 
et al.
17
 used side-effect profiles similarity to impute new pharmacological targets for 
known drugs, while Lounkine et al.
18
 employed structural similarity of drugs. Yang et 
al.
12
 used side effects as features of drugs to build classification models of drug 
indications, while Simon et al.
22
 used protein interaction profiles of drugs. Moreover, 
there are many studies focusing on large-scale prediction of chemical-protein interactions 
4 
 
per se
26,27
, which can provide useful input. Another group of studies derives statistical 
models to predict drug side-effects (Table 1.1, “C-E” in the “Goal” column) based on 
chemical structure, drug-target interaction profiles, and even drug indications as 
features
17
.  
Finally, an increasing number of studies attempt to consider the entire network of 
drug/target/effect relationships (Table 1.1, “Network” or “Inference” in the “Methods” 
column), often reporting the integrated view in form of a database
19,20
. Predictions are 
generated in the form of probabilities of network connections
15
 or as network-based 
inferences
21
.   
Despite these advances, there are still several challenges facing informatics-based 
ADE prediction. Collections such as FAERS are voluntary; many ADE occurrences do 
not get reported due to perceived lack of time or utility on the part of the clinician or 
patient. Conversely, many case reports alleging a causative association between a drug 
and an ADE may be confounded by concomitant medications, the patients' comorbidities, 
or other factors, and thus may contribute to a high false positive rate. On the surface, 
information-based ADE prediction strategies may seem (relatively) inexpensive, but they 
still rely on prior in vitro or in vivo discoveries, which in themselves are resource-
intensive as mentioned.  
Following the aforementioned Swanson’s ABC paradigm, this study aims to 
identify unknown relationships between chemicals (C), protein targets (T), and ADEs (E) 
in a resource-effective way. The formation and initial analysis of a C-T-E knowledge 
base are described here. First, known relationships between Cs, Ts, and Es are collected 
from several pharmacological and biomedical data sources. These relationships are 
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curated and integrated according to Swanson’s paradigm to form C-T-E triangles. They 
are then priority-scored to facilitate inference of and hypothesis generation for previously 
unreported chemical-ADE (C-E) relationships. 
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2. METHODS 
2.1 Chemicals (C) 
The initial list of chemicals was extracted from the NIH Chemical Genomics 
Center’s Pharmaceutical Collection (NPC), a publicly-accessible database containing ca. 
15,000 approved and investigational drugs
28
. A chemical curation process (Figure 2.1) 
pared this list down to 7,523 chemicals. Chemicals with non-standard SDF blocks were 
removed. Since the intended focus of this study was on small-molecule organic 
compounds, those that were tagged in NPC as “biologics”, “inorganics”, or “structure 
undefined” (these were often mixtures) were removed. Compounds with MW > 3 kDa 
were removed, as well. Additional inorganics, metallo-organics, and mixtures were 
removed via Pipeline Pilot Professional Client ver.9.1 (Accelrys) and ChemAxon 
Standardizer ver.6.0 following previously published curation workflow.
29
 Duplicate 
chemicals detected via canonical SMILES and InChiKey were set aside using Knime 
ver.2.6.2, a graphical data analytics workbench
30
. The Molecular Modeling Lab’s 
standard curation workflow
29
 was then applied, and additional errors were found. For 
instance, the structural duplicates found by Hit QSAR
31
 were analyzed, and true 
duplicates were removed. Cases in which a mixture was misrepresented by only one 
compound were removed. Then, incorrect name-to-structure annotations, 
stereochemistries, and structures in certain cases were fixed. In addition, incorrect 
PubChem CIDs were fixed or removed. One entry where an excipient was labeled as the 
primary chemical was removed, leaving 7,448 chemicals. 
Figure 2.1 Workflow for selecting study chemicals from the NPC database. 
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2.2 Targets (T) 
The list of protein targets was obtained from the Therapeutic Target Database 
(TTD), another publicly-accessible database containing pharmacological information on 
2,071 known or investigational therapeutic targets
32
. To facilitate the interoperability 
between multiple data sources, a restrained set of 1,280 targets with associated UniProt 
IDs were retained for this project (Figure 2.2).  
Figure 2.2 Workflow for selecting study targets from the TTD database. 
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2.3 ADEs (E) 
A list of ADEs was obtained from the Side Effect Resource (SIDER)
33
, a public 
knowledge source listing of established (known) ADEs of therapeutic agents extracted 
from the drug products’ package inserts. Only the 4,492 ADEs with unique UMLS 
concept IDs were retained for this project, again for facilitating interoperability
33
. A 
summary of these data is shown in Table 2.1. 
Table 2.1 Data sources from which the lists of chemicals, targets, and ADEs in this 
study were selected. 
 
Entity Data source 
Number of 
Entities 
Citation 
Date 
Accessed 
Chemicals 
(C) 
NCGC 
Pharmaceutical 
Collection (NPC) 
14,814 
chemicals 
Huang R et al. Sci. 
Transl. Med. 3, 
80ps16 (2011). 
11/19/2012 
Targets 
(T) 
Therapeutic 
Targets Database 
(TTD) 
2,071 
targets 
Zhu F et al. Nucleic 
Acids Res. 40(D1): 
D1128-1136, 2012. 
1/11/2013 
ADEs 
(E) 
Side Effect 
Resource 2 
(SIDER) 
4,492 
effects 
Kuhn M et al. Mol 
Syst Biol. 2010;6:343. 
Epub 2010 Jan 19. 
12/17/2012 
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2.4 Establishing pairwise associations 
 Known C-T, T-E and C-E associations, or edges, were collected. C-T edges were 
obtained from two data sources: the Search Tool for Interactions of Chemicals 
(STITCH)
34
, and the Comparative Toxicogenomics Database (CTD)
35
. STITCH contains 
information on chemical-protein interactions for 300,000 small molecules, 2.6 million 
proteins, and over 1000 organisms. CTD describes associations between chemicals, 
genes, and diseases in the framework of gene ontology and biochemical pathways, 
covering 887,000 chemical-gene associations, 13.5 million gene-disease associations, and 
1.5 million chemical-disease associations. T-E edges were obtained from CTD, as well. 
Known C-E edges were extracted from SIDER, CTD, and ChemoText (CT)
36
. CT is a 
knowledgebase of relationships between chemicals, targets, and ADEs extracted from 
MEDLINE annotations, covering 1.2 million chemical-target associations, 1.9 million 
target-disease associations, and 9.4 million chemical-disease associations. A summary of 
the data sources used to obtain these C-T, T-E, and C-E edges is shown in Table 2.2. 
Table 2.2 Data sources from which information regarding the associations between 
chemicals, targets, and ADEs in this study were obtained. 
 
Entity
a
 Data source Citation 
Date 
Accessed 
Original # 
Entities 
b
 
# Entities 
Included for 
AE Inference 
C→T 
Search Tool for 
Interactions of 
Chemicals 
(STITCH) 
Kuhn et al
34
 10/9/12 
787,889 
associations 
76,400 
associations 
Comparative 
Toxicogenomics 
Database (CTD) 
Davis et al
35
 9/12/12 
1,435,948 
associations 
T→E CTD (see above) (see above) 
12,364,098 
associations 
1,128,542 
associations 
Known 
C→E 
ChemoText 
(CT) 
Baker et al
36
 9/13/12 
10,916 
associations 
362,408 
associations CTD (see above) (see above) 
4,269,771 
associations 
SIDER Kuhn et al
33
 10/17/12 520,145 
10 
 
associations 
a 
For the details on C, T, and E entries, see online repository at 
http://arc.irss.unc.edu/dvn/dv/CTE_inferences; b After initial data curation. 
 
2.5 Data curation and representation  
Each data source may refer to its chemicals, targets, and ADEs using different 
identifier schemes. For example, STITCH refers to chemicals using STITCH IDs (which 
are derived from PubChem CIDs), whereas CTD uses CAS registry numbers. Thus, a 
common identifier scheme for chemicals, targets, and ADEs had to be established. For 
chemicals, an internal identifier system (Ch0000-Ch7522) was used for the remainder of 
the study. Although after finishing curation, the number of chemicals was decreased to 
7,448, the original Ch0000-Ch7522 chemical identification scheme was kept. UniProt 
IDs were selected to refer to targets. UMLS
37,38 (Unified Medical Language System; 
ver.2013AB) concept unique identifiers (CUIs) and MedDRA
39 Lowest Level Term IDs 
(Medical Dictionary for Regulatory Activities; accessed 2013) were used to refer to 
ADEs. Interconversion between the different identifier schemes was facilitated by 
UniProt’s ID mapping service40,41 (for target ID mapping) and the Chemical Translation 
Service (for chemical ID mapping; http://cts.fiehnlab.ucdavis.edu/) developed by 
Wohlgemuth and colleagues
42
, in addition to mappings present within some of the data 
sources themselves. Likewise, the pool of C→T, T→E, and C→E edges extracted from 
the various data sources were merged to consolidate information for the same entity that 
was represented across multiple data sources. The number of C-T, T-E and known C-E 
edges before and after merging are listed in Table 2.2. The chemicals, targets, ADEs, and 
the edges between them were stored as tables in an Oracle database ver.11, and accessed 
via RazorSQL ver.5.5.5 (Richardson Software, LLC), a database browser and 
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management tool. Auxiliary information stored with each edge included the number and 
PubMed IDs (PMIDs) of their article lists in which the edge’s vertices, e.g., C and T for a 
given C→T edge, were co-annotated. These PMIDs were obtained from the data sources 
informing each edge listed in Table 2.2.  
2.6 Inference procedure 
 Swanson’s ABC paradigm6 was used to make C-E inferences in the following 
way: if an edge existed between chemical C and target T (C→T), and another edge 
existed between T and E (T→E), then an edge between C and E (C→E) was inferred. It 
was possible for a C→E inference to have multiple linking targets. That is, C→E could 
be inferred not only via C→T1 and T1→E, but also via C→T2 and T2→E. The unique 
C→E inference was stored with its list of linking targets, as well as the number and 
PMIDs of articles which were co-annotated with the C→T and T→E edges that informed 
the C→E inference. This inference strategy and grouping of linking targets was 
implemented in Knime. After the C→E inferences were made, the entire list of C→E 
edges could be categorized into three sets: 1) known (i.e., previously reported, and 
obtained from SIDER, CTD, and/or CT) and inferred C→E, 2) known and not inferred 
C→E, and 3) inferred and not known C→E. 
2.7 Inference scoring 
 To prioritize C→E inferences for further investigation, three scoring systems 
were considered for ranking the C→E inferences. Article counts (AC) described the 
cardinality of the union of the C→T and T→ article lists. Linking target counts (LTC) 
described the number of linking targets bridging the C→E inference. Mutual information 
12 
 
(MI) relies on article count tables, and reflects how well-connected two vertices are to 
each other (see Appendix 1: Scoring Systems for a more detailed explanation). MI 
quantifies interdependency of two variables (0 for being independent). It is a basis for 
likelihood ratio G test, which is generally more powerful than chi squared test. Receiver 
operating characteristic (ROC), ROC enrichment, and precision-recall (PR) curves were 
used to compare the performance of each scoring system and select one scoring system 
for ranking C→E inferences. Known C→E edges were used as the “true” cases, while the 
inferred C→E edges were decoy cases. 
2.7.1 Substudy 1 - Restriction of target and ADE lists 
To facilitate closer analysis of the C→E inferences, the lists of Ts and Es were 
reduced. The known C-T and T-E edges were analyzed to find the top 100 occurring Ts 
in each set. The union of these sets of Ts would be retained from the original target list. 
Similarly, the set of Es was filtered to retain the “pharmacovigilance-relevant” ADEs, 
which have been associated with drugs’ market withdrawal, black box warnings, and/or 
hospitalizations based on analysis of scientific literature, FAERS, and other biomedical 
references
43,44
. 
2.7.2 Substudy 2 – Restriction of ADE list only 
Out of concern that limiting the set of Ts to just the most promiscuous targets 
would result in “noisy” inferences (i.e., many C→E inferences would be ranked equally 
by LTC), the  restrictions on the T list were lifted, and just limited the set of Es to those 
that were pharmacovigilance-relevant as described in Section 2.7.1. 
2.8 Inference and inference strategy validation 
13 
 
 This inference strategy was validated in several ways. Case reports linking C and 
E for a given C→E inference, and published after the C→E inference was made, 
provided primary literature confirmation for some C→E inferences. The proportion of 
known C→E associations captured by inferred C→E associations was computed.  
2.8.1 Substudy 3 – Timestamping and time-split validation 
 This substudy implemented a time-split validation technique, with the aims of 1) 
validating the forward-prediction abilities of the ABC inference strategy, and 2) 
evaluating the proportion of C→E inferences that could be confirmed over time. All 
edges from the described integrated knowledgebase were further characterized by 
timestamping, which overall sought to identify the earliest year by which an edge could 
be established. For known C→T, T→E, and C→E edges with article lists (i.e., papers 
that co-annotate or establish an association between known C→T, T→E, or C→E), their 
timestamps were determined by the earliest publication year of the papers in their article 
lists. If a known edge was listed in its data source(s) without an article list, no timestamp 
was assigned. For inferred C→E associations, their timestamps were determined by the 
later of the constituent C→T and T→E edges’ timestamps. That is, the timestamp 
represents the latest year at which there was enough information on C→T and/or T→E so 
that the C→E inference could be made. If either constituent C→T or T→E edge did not 
have a timestamp, the inferred C→E edges timestamp defaulted to that of whichever edge 
did have an assigned timestamp.  
 The timestamping substudy was conducted as shown in Figure 2.3. 
Figure 2.3 Time-split substudy workflow. 
14 
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3. RESULTS 
3.1 Analyzing the CTE database 
From the selected data sources (Table 2.1 and 2.2) and after additional rounds of 
chemical curation, 7,448 chemicals, 1,280 targets, and 4,492 ADEs, as well as 76,400 
C→T edges, 1,128,542 T→E edges, and 362,408 known C→E edges, were extracted. 
Figure 3.1 depicts the extent of entities covered by the identified edges based on raw 
data. The results discussed here have been updated as much as possible given time and 
resource constraints. It is acknowledged that the biomedical literature grows each day 
with new C→E associations and other discoveries. Despite this growth, these results were 
attained using current protocols for data curation (which also undergo continual 
improvements). Significant changes to these results are not expected, but minor changes 
in size of data and some of the derivative values may change. 
Figure 3.1 Summary of collected chemicals (C), targets (T), ADEs (E), and the 
known associations between each vertex, as well as the C→E associations inferred 
based on known information. 
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Among chemicals with at least one connection, 44% were associated with 5 or fewer 
targets; at the same time, 39% of such chemicals had associations with over 100 ADEs 
(Figure 3.2).  
Figure 3.2: Distribution of associations from chemicals to targets and ADEs (raw 
data). Chemical-target edges were extracted from STITCH and CTD, while chemical-
ADE edges were extracted from CTD, SIDER, and ChemoText. The inset shows an 
example of a chemical known to be associated with many targets and ADEs. 
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Once information regarding vertices (chemicals, targets, and ADEs) and edges was 
compiled and organized into CTE triangles, 5,841,274 unique C→E associations were 
inferred. These correspond to ~17% of all possible associations in a matrix of 7,448 
chemicals and 4,492 ADEs, i.e., 83% sparsity degree. This CTE network has been 
visualized in Figure 3.3.  
Figure 3.3 Network visualization. Network visualization (A) of interconnected 
chemicals (blue), targets (green), and ADEs (red) interconnections, connectivity clusters 
in each domain (B), and a subnetwork for paroxetine-thrombocytopenic purpura 
inference (C). 
 
18 
 
 
There were 341,453 C→E edges that were both previously reported (known) and inferred 
from the ABC strategy (Figure 3.4).  
Figure 3.4 Comparison of known vs. inferred C-E edges (coverage of known C→E 
edges = 94%). 
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Inference of C→E edges via the ABC paradigm was able to capture 94% of the known 
C→E edges. The majority of inferred C→E edges (57%) had few (≤ 5) linking targets 
(Figure 3.5). 
Figure 3.5 Distribution of inferred, previously unreported chemical-ADE edges, 
binned by the number of targets that link the same chemical and effect together 
(raw data). 
 
 
3.2 Substudy 1 – Restriction of Target and ADE Lists 
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The restriction of the set of Ts provided a list of 153 targets (see online repository 
at http://arc.irss.unc.edu/dvn/dv/CTE_inferences), retained from the original (n = 1280) 
target list. From the C-T edge list, the most common Ts were CYP3A4, TNF-α, and 
MDR1. The set of Es was filtered to retain 164 ADEs that were “pharmacovigilance-
relevant” (see online repository at http://arc.irss.unc.edu/dvn/dv/CTE_inferences). There 
were 47,078 C→E inferences remaining after the number of Ts and Es were reduced 
(new sparsity: 96%). Pulmonary valve incompetence, thrombocytopenic purpura, and 
aortic valve incompetence were the three most common ADEs. 
 Of the three scoring systems considered, article count (AC) appeared to have the 
best overall performance in this reduced C→E inference set, though linking target count 
(LTC) had the best early enrichment. The top ten prioritized C→E inferences by each 
scoring system are shown in Appendix 2 (raw data). The top 45 LTC-prioritized C→E 
inferences (“generated hypotheses”) were selected for further investigation. (Appendix 
3). 
3.3 Substudy 2 – Restriction of ADE List Only 
 When just limiting the set of Es to those that were pharmacovigilance-relevant 
(164 ADEs), there were 286,815 C→E inferences remaining from the original ~6 million 
C→E inferences (new sparsity degree 77%). There were 76 unique ADEs represented. 
Drug-induced liver disease, renal failure acute, acute renal insufficiency, and liver 
disorder were the most common ADEs on this list. 
 For this E-only limited C→E inference list, LTC appeared to have the best overall 
performance for separating known inferences (area under receiver operating 
characteristic curve, ROC AUC = 0.84, Appendix 4), though mutual information (MI) 
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had the best early enrichment (~100-fold at 0.01% of the ranked list, Appendix 4). The 
C→E inferences were thus sorted by MI, and the top ten prioritized C→E inferences by 
each scoring system are shown in Table 3.1.  
Table 3.1 Top 10 C→E inferences as ranked by mutual information (MI) and 
linking target count (LTC). The original list of C→E inferences has been restricted in 
Es to retain pharmacovigilance-relevant Es (164 Es). 
 
Ranked by Mutual Information  
(MI score 
a
) 
Ranked by Linking Target Count  
(LTC score 
b
) 
1 doxorubicin → chest pain (8.63 x 10
-5
) estradiol → confusional state (498) 
2 
pilocarpine → torsades de pointes (8.19 x 
10
-5
) 
clofezone → vomiting (470) 
3 
tretinoin → extrapyramidal disorder (6.40 x 
10
-5
) 
clofezone → hemolytic anemia (462) 
4 
testosterone → drug-induced liver disease 
(6.30 x 10
-5
) 
clofezone → diarrhea (462) 
5 
testosterone → seizure [Convulsions 
generalized, Clonic convulsion, Convulsive 
seizure] (4.79 x 10
-5
) 
clofezone → drug eruption (462) 
6 
indomethacin → torsades de pointes (4.16 x 
10
-5
) 
clofezone → pneumonia (460) 
7 pilocarpine → sudden death (4.08 x 10
-5
) 
clofezone → thrombosis [Venous 
thrombosis, Deep vein thrombosis] (458) 
8 
phenylephrine → thrombocytopenia (3.84 x 
10
-5
) 
clofezone → rhabdomyolysis (458) 
9 
testosterone → myocardial infarction (3.82 x 
10
-5
) 
clofezone → pancreatitis (457) 
10 testosterone → hypotension (3.80 x 10-5) estradiol → death (455) 
a 
MI had mean 4.56 x 10-7, median 1.79 x 10-8, and range 9.67 x 10-17 to 1.96 x 10-3; 
b 
LTC 
had mean 16.7, median 6, and range 1 to 501. 
3.4 Inference and inference strategy validation 
3.4.1 Case Studies 
 Case studies were identified from primary literature published after the inference 
was made (the latter date being, at the latest, January 11, 2013). When the restricted 
Ts/restricted Es list of C→E inferences were prioritized by LTC (Appendix 2), the 
inference between paroxetine and thrombocytopenic purpura (TP) ranked first. 
Paroxetine, a selective serotonin reuptake inhibitor, was linked to TP via 22 targets (see 
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Figure 3). These targets include caspase-3 (CASP3) and signal transducer and activator 
of transcription 3 (STAT3). Paroxetine increases CASP3 activation. CASP3 activation is 
associated with idiopathic thrombocytopenic purpura
45
, and its inhibition is associated 
with blocking apoptosis mediated by plasma from thrombotic thrombocytopenic purpura 
and hemolytic-uremia syndrome patients
46
. Paroxetine suppresses STAT3 expression
47
, 
and decreased STAT3 dimerization and general lack of JAK2 pathway activation is 
associated with thrombocytopenic purpura
48,49
.  
 When the restricted Es list of C→E inferences was prioritized by MI, the 
inference between testosterone and myocardial infarction via 183 linking targets ranked 
ninth. These targets include TNF-α and c-Fos. Testosterone increases TNF-α 
production
50
. While the relationship between increased TNF-α production and 
myocardial infarction is not a definitively causative one, increased levels of the 
inflammatory cytokine have been observed during initial and recurrent myocardial 
infarctions
51
, and have been associated with post-event myocardial injury
52
. Similarly, 
testosterone induces c-Fos expression
53
, which may have a role in myocardial infarction 
pathogenesis
54
. Two independent retrospective studies
55,56
 have been conducted that both 
demonstrated an association between testosterone and negative cardiovascular outcomes, 
including myocardial infarction and stroke. At this time, the FDA is investigating this 
association based on the results of these two studies. 
 The top 50 MI-ranked C→E inferences (again, restricted by pharmacovigilance-
relevant Es) were selected for further investigation (Figure 3.4 and Appendix 5).  
Figure 3.6 Analysis of top 50 ranked C→E inferences from Substudy 2. Rankings are 
based on pharmacovigilance-relevant adverse effects ranked by mutual information score. 
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Although 5 (10%) inferences could be confirmed as causative, another 4 (8%) inferences 
were confirmed as therapeutic, i.e., the chemical ameliorated the associated effect. Seven 
(14%) inferences were classified as “conflicting”; i.e., there were articles reporting the 
chemical causing the effect, as well as mitigating the effect. Half of the inferences could 
not be confirmed in the biomedical literature. This does not mean that these inferences 
were erroneous, but no articles that co-annotated the chemical and effect could be found 
as of today. 
Other inferences that were validated in the literature reports that appeared after 
the publications used for making the inference include ciprofloxacin →  posterior 
reversible encephalopathy syndrome (PRES)
57
, and rifaximin →  toxic epidermal 
necrolysis syndrome (TENS)
58
.   
3.4.2 Substudy 3 – Timestamping and time-split validation 
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Following the workflow illustrated in Figure 2.3, the first aim of time-split 
substudy sought to evaluate how well the ABC inference strategy predicts later-known C
→E associations. Consider the example of a cutoff year of 1992 (Step 2 of Figure 2.3). 
There were 241,817 known C→E associations established (i.e., with timestamp) after 
1992 (Step 3). Based on the C→T and T→E associations established prior to 1992, there 
were 497,537 C→E inferences that could be made prior to 1992, of which 69,844 C→E 
inferences were also confirmed after 1992 (Steps 4-5). This yields a post-1992 coverage 
rate of 69,844 / 241,817 = 29%, i.e., 29% of C→E associations established after 1992 
could have been inferred using the described ABC strategy prior to 1992 (Step 6). In 
addition, the time-split substudy assessed the rate of C→E inferences that would later be 
validated post-cutoff year. There is a validation rate of the pre-1992 C→E inferences of 
69,844 / 497,537 = 16%, i.e., 16% of C→E inferences that could have been made prior to 
1992 were later confirmed (Step 6). These steps were repeated in 5-year increments for 
the years 1987-2007 (Figures 3.5 and 3.6). The size over time of the C→E association 
sets (i.e., C→E inferences that could be made prior to a cutoff year, C→E associations 
established after the cutoff year, and the intersection of these sets) is shown in Figure 
3.7. The full table of C→E association counts by cutoff year is listed in Appendix 6. 
Figure 3.7: Post-cutoff year coverage rates from Substudy 3. C→E inferences that 
could be made with C→T and T→E edges published prior to certain years (1987-2007 in 
5-year intervals), and their coverage of the known C→E edges published after that given 
year. The total number of known C→E edges established after a given cutoff year is 
listed above each bar. 
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Figure 3.8 Pre-cutoff year validation rates from Substudy 3. The percentage of C→E 
inferences that could be made prior to a given cutoff year that were later validated. The 
total number of inferred C→E edges that could be established prior a given cutoff year is 
listed above each bar. 
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Figure 3.9 Trends in size of C→E association sets from Substudy 3. The green line 
relates to Step 3 of the time-split substudy workflow, the blue line relates to Steps 4-5, 
and the red line relates to Step 6. 
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4. DISCUSSION 
 In this work, publicly-available knowledge bases describing known associations 
between chemicals, targets, and ADEs were used to infer unknown associations between 
drugs and ADEs. While our strategy was able to recover 94% of previously reported C-E 
associations, there was still a small fraction (~21K) of known C-E associations that 
remained unpredicted. This may occur if no targets are discovered during the initial data 
collection and curation steps that link the chemical to effect, or it could happen for known 
C-E associations if the pathophysiology behind the association has not been fully 
elucidated. For example, the bisphosphonate alendronic acid is known to cause 
osteonecrosis of jaw (ONJ), and this pair is on our list of previously-reported C-E 
associations. However, it could not be inferred through the ABC strategy since the 
alendronic acid-T associations and T-ONJ shared no common linking targets. The 
mechanism linking bisphosphonates to ONJ is still not well understood
59
.  
The results of our study compare favorably with those of previous computational 
approaches to ADE prediction. Yamanishi and colleagues
13
 used several approaches to 
analyze 658 drugs, 969 ADEs, and 23,061drug-ADE associations. The best-performing 
one yielded an area under the precision-recall curve (AUPR) of 0.21 ± 0.0024. When 
scoring by MI, our inference strategy yielded an AUPR of 0.48 (Appendix 4). Mathur et 
al.
25
 used network analysis techniques to predict associations between biological 
processes and drugs via known information about related diseases, drugs, and targets. 
Several databases, including Swissprot, OMIM, and GeneRIF, were used to inform 
known relationships. They report 2,222 drug-disease associations involving 76 drugs and 
169 diseases, of which 144 (6.4%) were confirmed in DrugBank
25
. Of the ~6 million C-E 
inferences produced with the ABC strategy described above, 341,453 (5.8%) C-E 
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inferences were confirmed in SIDER
33
, ChemoText
36
, and/or CTD
35
 (Figure 3.4). 
Despite our lower confirmed C→E rate, a larger number of chemicals and effects were 
included for consideration in this study, with the C-E inferences involving 4,053 
chemicals and 1,743 effects (raw data). “Chemicals” include not only drugs but also 
drug-like compounds, whose physiologic effects may not be as well characterized as 
drugs in most of the available pharmacology or ADE databases. 
The time-split substudy identified C→E inferences that were “novel” – not from 
the perspective of the present, but from the viewpoint of when the constituent C→T/T→
E edges were established. The percentage of known C→E associations that could have 
been predicted earlier using the ABC strategy seemed to increase over time, from 18% of 
post-1987 C→E associations to 88% of post-2007 C→E associations. This increase in 
coverage may be due to the natural growth of information available (discoveries about C
→T and T→E) over time, combined with the decreasing number of C→E associations 
established after the cutoff year, as the cutoff year increases. The percentage of inferred C
→E associations that were later confirmed appeared to decrease over time, from 21% of 
pre-1987 C→E inferences to 2% of pre-2007 C→E inferences. This observation may not 
be due to decreasing accuracy, but rather due to the calculation of the percentage itself. 
The number of pre-cutoff year C→E inferences grows precipitously over time (large and 
increasing denominator), while the number of inferred and validated C→E associations 
stays relatively stable (smaller numerator). The time-split validation method could be 
pursued further as a strategy to identify characteristics of C→E inferences, or their 
constituent C→T/T→E edges, that would make them more likely to be predicted and 
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confirmed, and thus used to prioritize C→E inferences for further investigation. Because 
our strategy did not distinguish between causative vs. therapeutic C→E inferences, our 
initial research hypothesis may be modified in moving forward to include annotating C→
T and T→E edges with more information regarding the specific type of interaction, 
which may help with differentiating causative vs. therapeutic C→E inferences. 
This study had certain limitations. The C→E inferences were limited to the 
“knowledge universe” of data sources used. Only an association between a C and an E 
can be inferred; it is not possible to distinguish, without further characterization of edges, 
between therapeutic and causative C→E associations. It may be computationally 
expensive to update the current collection of C→T, T→E, known C→E, and inferred 
C→E edges, since new associations would need to be made, and revised scores 
calculated. This inference strategy does not replace clinical judgment; in fact, manual 
intervention is required to process even the prioritized list of C→E inferences. For 
example, "Convulsion", "Convulsions generalized", "Clonic convulsion", and 
"Convulsive seizure" are all considered separate concepts in this C-T-E system, but have 
been manually grouped together as seizure, especially if they were all inferred to be 
associated with the same chemical with the same ranking score. Moreover, this inference 
strategy does not attempt to predict the dose at which an ADE would occur for a 
particular chemical, nor does it predict the frequency of this ADE occurring with 
exposure to the chemical. The inference strategy is limited by the “universe” of 
knowledge it is based on, which affects both quantity and quality of inferences. 
 There are several future directions that could be explored. Identifying other 
subsets of C→E inferences for further study may be instructive. Though 
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pharmacovigilance-relevant ADEs were the focus of the current study, it would be 
interesting to investigate inferences implicating the top 200 marketed drugs, or to focus 
on inferences involving G-protein coupled receptors. The same inference strategy could 
be used for drugs in the development pipeline, to identify potential ADEs that the drug 
could cause prior to in vivo testing. New ADE predictions could be made or strengthened 
based on structural similarity with chemicals participating in known C→E associations. 
Rules of similarity for chemicals sharing the same T and E could be rationalized. 
Inferences could be made for not only C→E associations, but also C→T and T→E edges; 
these studies may help with elucidating a drug’s mechanism of action, or link 
pharmacological action at a target with a specific ADE.  
 In conclusion, the work presented here has established and characterized a 
knowledgebase that integrates chemical, target, and adverse effect information 
across multiple publicly-accessible databases. As shown by the aforementioned case 
studies and ranking schemes, our knowledgebase has the potential to facilitate the 
early inference and prioritization of some previously unreported chemical-ADE 
associations, which could have implications in cost savings and patient outcome in 
the drug development process. 
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APPENDICES 
Appendix 1. Scoring Systems 
Three scoring systems were evaluated for prioritizing C→E inferences. 
 Linking target count – The number of targets through which the C and E in the 
C→E inference interact. 
 Direct article counts – The number of articles linking the C with E, across all 
linking T? 
𝑑𝑖𝑟𝑒𝑐𝑡 𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑐𝑜𝑢𝑛𝑡𝑠 = |⋃(𝑃𝑀𝐼𝐷𝑠𝐶𝑇𝑖 ∪ 𝑃𝑀𝐼𝐷𝑠𝑇𝑖𝐸)
𝑛
𝑖=0
| 
 Mutual information – This value reflects how interdependent two variables are, 
with 0 being completely independent and higher values denoting increased 
dependence. The MI is the basis for the likelihood ratio G test. The MI makes use 
of article count tables, tallying the number of articles within a body of literature 
that does mention (1) or does not mention (0) a particular entity. 
 
Consider a C→E inference constructed via C→T1 and T1→E, as well as through 
C→T2 and T2→E. Article count tables can be constructed for the C→T1→E and 
C→T2→E inferences, then converted into frequency tables. For example, in the 
below tables, the literature corpus contains 58,962 articles which mention neither 
C nor T1 (C = 0, T1 = 0), 26 articles mentioning C but not T1 (C = 1, T1 = 0), 
10,810 articles mentioning T1 but not C (C = 0, T1 = 1), and 3 articles in which C 
and T1 are co-annotated (C = 1, T1 = 1). 
 
Article Count Tables  Frequency Tables 
 C = 0 C = 1 
T1 = 0 58,962 26 
T1 = 1 10,810 3 
 
convert to 
frequencies 
→ 
 C = 0 C = 1 
T1 = 0 0.84 3.72 x 10
-4
 
T1 = 1 0.15 4.30 x 10
-5
 
 
 T1 = 0 T1 = 1 
E = 0 58,960 10,809 
E = 1 28 4 
 
convert to 
frequencies 
→ 
 T1 = 0 T1 = 1 
E = 0 0.84 0.15 
E = 1 4.0 x 10
-4
 5.73 x 10
-5
 
 
 
The frequency tables can be used to compute MI scores for the individual edge. 
The MI score for the C→E inference through one linking target (e.g. C→T1→E) 
can be computed by multiplying the MI scores of C→T1 and T1→E. The MI score 
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for the C→E inference through all its linking targets can be computed by 
summing the MI scores across all linking targets. 
 
𝑀𝐼𝐶𝑇 = ∑ ∑ 𝑝(𝐶𝑇) ∙ 𝑙𝑜𝑔2 (
𝑝(𝐶𝑇)
𝑝(𝐶) ∙ 𝑝(𝑇)
)
𝑇=0,1𝐶=0,1
 
 
𝑀𝐼𝑇𝐸 = ∑ ∑ 𝑝(𝑇𝐸) ∙ 𝑙𝑜𝑔2 (
𝑝(𝑇𝐸)
𝑝(𝑇) ∙ 𝑝(𝐸)
)
𝐸=0,1𝑇=0,1
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Appendix 2. Substudy 1 results – Restriction of target and ADE lists 
 
The top 10 C→E inferences as ranked by linking target count (LTC) and article count 
(AC) from Substudy 1 (raw data). The original list of C→E inferences has been restricted 
by Ts and Es to retain the most commonly implicated Ts (153 Ts) and 
pharmacovigilance-relevant Es (164 Es). 
 
Ranked by Linking Target Count 
(Number of linking targets) 
Ranked by Article Count (Number of 
articles) 
1 
paroxetine → thrombocytopenic purpura 
(22) 
tiotropium → seizure [Convulsion, 
Convulsions generalised, Clonic convulsion, 
Convulsive seizure] (1924) 
2 daunorubicin → epidermolysis bullosa (21) 
alvameline → seizure [Convulsion, 
Convulsions generalised, Clonic convulsion, 
Convulsive seizure] (1912) 
3 
trifluoperazine → pulmonary valve 
incompetence (21) 
metipranolol → seizure [Convulsion, 
Convulsions generalised, Clonic convulsion, 
Convulsive seizure] (1909) 
4 sulindac (E) → dermatitis bullous (20) 
pipoxolan → seizure [Convulsion, 
Convulsions generalised, Clonic convulsion, 
Convulsive seizure] (1896) 
5 
telbivudine → pulmonary valve 
incompetence (20) 
perazine → seizure [Convulsion, 
Convulsions generalised, Clonic convulsion, 
Convulsive seizure] (1890) 
6 digitoxin → transient global amnesia (20) 
lutein → seizure [Convulsion, Convulsions 
generalised, Clonic convulsion, Convulsive 
seizure] (1888) 
7 benzenamine → dermatitis bullous (20) 
dimemorfan → seizure [Convulsion, 
Convulsions generalised, Clonic convulsion, 
Convulsive seizure] (1821) 
8 
cimetidine → pulmonary valve 
incompetence (19) 
blonanserin → seizure [Convulsion, 
Convulsions generalised, Clonic convulsion, 
Convulsive seizure] (1806) 
9 clarithromycin → anterograde amnesia (18) 
mosapramine → seizure [Convulsion, 
Convulsions generalised, Clonic convulsion, 
Convulsive seizure] (1806) 
10 
dexmedetomidine → extrapyramidal 
disorder (18) 
bindarit → seizure [Convulsion, 
Convulsions generalised, Clonic convulsion, 
Convulsive seizure] (1802) 
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Appendix 3. Substudy 1 top 45 previously-unreported C→E inferences, as ranked 
by linking target count.  
Target list is restricted to highly promiscuous targets, and ADEs are restricted to 
pharmacovigilance-relevant ones. C→E inferences without rank (“—”) denote previously 
reported associations. 
Rank Chemical Effect 
Linking 
Target Count 
Confirmed? 
1 paroxetine 
thrombocytopenic 
purpura 
22 Yes (2013)
60
 
2 daunorubicin 
epidermolysis 
bullosa 
21 
Cannot confirm; can 
associate doxorubicin 
with epidermolysis 
(1975)
61
 
3 trifluoperazine 
pulmonary valve 
incompetence 
21 Cannot confirm 
4 sulindac (E) dermatitis bullous 20 
Can associate 
sulindac with TENS 
(1988)
62
 
5 telbivudine 
pulmonary valve 
incompetence 
20 Cannot confirm 
6 digitoxin 
transient global 
amnesia 
20 Yes (1975
63
) 
7 cimetidine 
pulmonary valve 
incompetence 
19 Cannot confirm 
8 clarithromycin anterograde amnesia 18 
In combination with 
rabeprazole (2013
64
) 
9 dexmedetomidine 
extrapyramidal 
disorder 
18 Cannot confirm
65
 
10 medetomidine 
extrapyramidal 
disorder 
18 Cannot confirm 
11 domperidone anterograde amnesia 18 Cannot confirm 
— dexmedetomidine depressive disorder 18 
Yes, via alpha-2 
adrenoreceptor 
activity (2008
66
) 
— edaravone 
aortic valve 
incompetence 
18 Cannot confirm 
— medetomidine depressive disorder 18 
Cannot confirm; can 
associate 
dexmedetomidine 
with depressive 
disorder (2008
66
) 
12 masoprocol 
epidermolysis 
bullosa 
18 
Cannot confirm, but 
masoprocol is a 
topical antineoplastic 
agent 
13 medetomidine amnesia 18 Cannot confirm 
14 dexmedetomidine amnesia 18 Yes (2000
67
)  
15 medetomidine angina pectoris 18 Cannot confirm 
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Rank Chemical Effect 
Linking 
Target Count 
Confirmed? 
16 dexmedetomidine angina pectoris 18 
Cannot confirm, 
likely not causative; 
currently being 
studied to reverse the 
cardiovascular effects 
of cocaine
68
 
17 tranylcypromine anterograde amnesia 18 Cannot confirm 
18 dexmedetomidine 
gastrointestinal 
haemorrhage 
18 
Cannot confirm, 
likely not causative 
19 medetomidine 
gastrointestinal 
haemorrhage 
18 Cannot confirm 
20 neostigmine 
aortic valve 
incompetence 
18 Cannot confirm 
21 cilostazol 
pulmonary valve 
incompetence 
18 
Cannot confirm, 
likely not causative 
— dexmedetomidine abdominal pain 18 
Observed in post-
marketing 
surveillance
69
, but not 
confirmed causative 
— medetomidine abdominal pain 18 
Not observed in 
animals (2010
70
)  
— dexmedetomidine sepsis 18 
Cannot confirm, but 
may have benefits in 
sepsis patients; 
currently being 
studied in DESIRE 
trial
71
 
— medetomidine sepsis 18 Cannot confirm 
22 dexmedetomidine pneumonia 18 
Cannot confirm, 
sedation may increase 
infection risk 
23 medetomidine pneumonia 18 Cannot confirm 
24 nicotinic acid 
pulmonary valve 
incompetence 
18 Cannot confirm 
25 digoxin 
thrombocytopenic 
purpura 
18 
Cannot confirm; 
digoxin is associated 
with 
thrombocytopenia 
(1981
72
)  
26 selenomethionine 
extrapyramidal 
disorder 
17 Cannot confirm 
27 medetomidine venous thrombosis 17 Cannot confirm 
28 dexmedetomidine venous thrombosis 17 Cannot confirm 
29 medetomidine major depression 17 Cannot confirm 
30 dexmedetomidine major depression 17 Cannot confirm 
31 diethyldithiocarbamate 
pulmonary valve 
incompetence 
17 Cannot confirm 
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Rank Chemical Effect 
Linking 
Target Count 
Confirmed? 
32 racemethorphan 
thrombocytopenic 
purpura 
17 Cannot confirm 
33 medetomidine thromboembolism 17 Cannot confirm 
34 dexmedetomidine thromboembolism 17 Cannot confirm 
35 docosahexaenoic acid 
thrombocytopenic 
purpura 
17 
Cannot confirm; 
omega-3 fatty acids 
have been associated 
with antiplatelet 
effects
73
 
36 DEET anterograde amnesia 17 
Memory loss 
associated with 
DEET exposure
74,75
, 
but anterograde 
amnesia not specified 
— medetomidine pancreatitis 17 
Cannot confirm; 
medetomidine 
inhibits insulin 
secretion from rat 
pancreatic cells
76
 
37 dexmedetomidine pancreatitis 17 
Cannot confirm 
causation; 
dexmedetomidine 
inhibits insulin 
secretion from rat 
pancreatic cells
76
; 
pancreatitis was 
reported as a cause of 
death during 
dexmedetomidine 
use, but unclear if 
causative
77
 
38 medetomidine dermatitis 17 Cannot confirm 
39 dexmedetomidine dermatitis 17 Cannot confirm 
40 medetomidine asthenia 17 Cannot confirm 
41 dexmedetomidine asthenia 17 Cannot confirm 
42 nefazodone 
thrombocytopenic 
purpura 
17 
Observed in post-
marketing 
surveillance, but not 
confirmed causative
78
 
— bufuralol 
extrapyramidal 
disorder 
16 Cannot confirm 
— bufuralol 
grand mal 
convulsion 
16 Cannot confirm 
43 bufuralol 
gastrointestinal 
haemorrhage 
16 Cannot confirm 
44 bufuralol 
orthostatic 
hypotension 
16 Yes (1986
79
)  
45 bufuralol confusional state 16 Cannot confirm 
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Appendix 4. Substudy 2 scoring system performance.  
Derived from raw data. 
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Appendix 5. Substudy 2 top 50 previously-unreported C→E inferences, as ranked 
by mutual information.  
ADE list restricted to pharmacovigilance-relevant ones. C→E inferences without rank 
(“—”) denote previously reported associations. 
Rank Chemical Effect 
Mutual 
Information 
Score 
Comments 
1 doxorubicin chest pain 8.63E-05 
May be related to anthracycline-
related cardiotoxicity
80
 
2 pilocarpine torsades de pointes 8.19E-05 
Pilocarpine toxicity associated w/ 
arrhythmia, but cannot confirm 
specifically TdP
81
 
3 tretinoin 
extrapyramidal 
disorder 
6.40E-05 Cannot confirm 
4 testosterone 
drug-induced liver 
disease 
6.30E-05 
Confirmed, causative – (200282, 
2013
83
); LiverTox
84
 
5 testosterone 
convulsions 
generalized;  
clonic convulsion;  
convulsive seizure 
4.79E-05 
Conflicting, but cannot tell if 
proconvulsant or anticonvulsant - 
(2004: rats, in vivo, proconvulsant
85
; 
2013: DHT anticonvulsant
86
) 
6 indomethacin torsades de pointes 4.16E-05 
Confirmed, neither causative nor 
therapeutic (2001: canine, in vitro
87
) 
7 pilocarpine sudden death 4.08E-05 
Confirmed, causative (2007: rats, in 
vivo
88
; likely due to convulsant 
effects) 
8 phenylephrine thrombocytopenia 3.84E-05 Cannot confirm 
9 testosterone myocardial infarction 3.82E-05 
Confirmed, causative (November 
2013
55
; 2014
56
) 
10 testosterone hypotension 3.80E-05 
Confirmed not causative or 
therapeutic (testosterone associated 
w/ hypertension)
89
 
11 pilocarpine rhabdomyolysis 3.71E-05 
Cannot confirm – likely because 
pilocarpine is a proconvulsant 
12 isoprenaline chest pain 3.59E-05 Confirmed – angina90 
13 genistein 
extrapyramidal 
disorder 
3.57E-05 
Protective, not causative (2008; 
mouse model of Parkinson's 
Disease
91
) 
14 testosterone thrombocytopenia 3.51E-05 Cannot confirm 
15 vidarabine 
drug-induced liver 
disease 
3.42E-05 
Cannot confirm; this drug is usually 
used in context of HBV 
16 doxorubicin rhabdomyolysis 3.40E-05 
Not shown causative or therapeutic 
(1995
92
; 2002
93
) 
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Rank Chemical Effect 
Mutual 
Information 
Score 
Comments 
17 indomethacin 
extrapyramidal 
disorder 
3.37E-05 Cannot confirm 
18 estradiol 
mitral valve 
incompetence 
3.22E-05 Cannot confirm 
19 progesterone torsades de pointes 2.88E-05 
Protective (2011
94
); ongoing clinical 
trial
95
 is investigating 
20 acetaminophen chest pain 2.83E-05 Cannot confirm 
21 capsaicin chest pain 2.67E-05 
Depends on source of problem: 
- Digestive/GI pain: 
causative (2004: increased 
expression of capsaicin 
- TRPV1 receptor in 
inflamed human 
esophagus
96
; 2010
97
) 
Cardiovascular-related pain: 
therapeutic (2013
98
) 
22 cimetidine 
amnesia; amnesia 
transient; global 
amnesia 
2.49E-05 Cannot confirm 
23 testosterone neutropenia 2.47E-05 Therapeutic (1965
99
) 
24 acetaminophen  angina pectoris 2.44E-05 Cannot confirm 
25 streptozocin torsades de pointes 2.37E-05 Cannot confirm 
26 vidarabine 
convulsions 
generalized; 
convulsive seizure 
2.29E-05 Cannot confirm 
27 testosterone neuropathy peripheral 2.21E-05 
Conflicting – causative (1997100); 
therapeutic (2008
101
) 
28 dibucaine 
drug-induced liver 
disease 
2.14E-05 Cannot confirm 
29 pilocarpine thromboembolism 2.13E-05 Cannot confirm 
30 phenylephrine 
extrapyramidal 
disorder 
2.05E-05 Cannot confirm 
31 morphine torsades de pointes 1.99E-05 
Cannot confirm specifically TdP, 
but morphine can cause 
arrhythmias
102
 
32 estradiol confusional state 1.96E-05 Cannot confirm 
33 colforsin thrombocytopenia 1.91E-05 Cannot confirm 
34 rosiglitazone chest pain 1.87E-05 
Associated with angina (↑ CHF, MI 
risk)
103
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Rank Chemical Effect 
Mutual 
Information 
Score 
Comments 
35 testosterone mania 1.85E-05 
Conflicting – objective scores for 
mania increase w/ variable clinical 
significance (2000
104
); susceptible 
patients more likely to see ↑ mania, 
e.g. bipolar disorder or other 
interacting meds (1999
105
; 2012
106
; 
2014
107
) 
36 testosterone 
renal failure acute; 
acute renal 
insufficiency 
1.79E-05 
Conflicting – causative (2004108); 
therapeutic (2013
109
) 
37 hyoscyamine 
convulsion; 
convulsions 
generalized; clonic 
convulsion; 
convulsive seizure 
1.78E-05 
Conflicting – causative: PMID 
(1965: mice, in vivo
110
; ToxNet
111
); 
therapeutic, or at least non-causative 
(1994: male guinea pigs, in vivo
112
) 
38 risperidone 
amnesia transient; 
global amnesia 
1.75E-05 
Cannot confirm; risperidone used 
often in schizophrenia, which itself 
is associated w/ memory loss 
39 streptozocin chest pain 1.69E-05 
Cannot confirm in biomedical 
literature; patient literature advises 
to watch for chest pain
113
 
40 dopamine thrombocytopenia 1.67E-05 Cannot confirm 
41 glucose 
extrapyramidal 
disorder 
1.67E-05 
Neither causative nor therapeutic; 
cerebellar & brainstem glucose 
metabolism decreased in multi-
system atrophy (1996
114
) 
42 calcitriol 
extrapyramidal 
disorder 
1.66E-05 Cannot confirm 
43 glucose chest pain 1.63E-05 
Conflicting – strict blood glucose 
monitoring leading to hypoglycemia 
"more likely to be" associated w/ 
cardiac ischemia (2003
115
); but high 
postchallenge glucose levels 
associated w/ CHD in Japanese men 
(1987
116
) 
44 mifepristone thrombocytopenia 1.59E-05 
Associated w/ thrombotic 
thrombocytopenic purpura (2007
117
) 
45 estradiol anterograde amnesia 1.58E-05 Protective – conference abstract118 
46 diethylstilbestrol torsades de pointes 1.54E-05 Cannot confirm 
47 genistein major depression 1.53E-05 Therapeutic (2014
119
) 
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Rank Chemical Effect 
Mutual 
Information 
Score 
Comments 
48 
dinoprostone 
(prostaglandin 
E2) 
torsades de pointes 1.52E-05 Therapeutic (1981
120
; 2003
121
) 
49 
Testosterone 
phenylacetate 
depressive disorder 1.51E-05 Therapeutic (2003
122
; 2009
123
) 
50 isocycloheximide 
extrapyramidal 
disorder 
1.50E-05 Cannot confirm 
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Appendix 6. Substudy 3 table of C→E association counts  
Timestamp 
Number of 
C→E 
Associations 
Inferred 
Prior to 
Cutoff Year 
Number of 
C→E 
Associations 
Established 
After 
Cutoff Year 
Number of 
C→E 
Associations 
Inferred 
Prior to 
Cutoff Year 
and 
Confirmed 
After 
Cutoff Year 
Post-Cutoff 
Year 
Coverage 
Rate 
Achieved 
by ABC 
Inference 
Strategy 
Pre-Cutoff 
Year 
Validation 
Rate 
1987 227,006 262,146 46,754 18% 21% 
1992 427,693 241,817 69,844 29% 16% 
1997 830,213 206,704 98,755 48% 12% 
2002 1,454,652 142,585 99,571 70% 7% 
2007 2,303,273 57,486 50,713 88% 2% 
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DISCLAIMERS 
Some material in the UMLS Metathesaurus is from copyrighted sources of the respective 
copyright holders. Users of the UMLS Metathesaurus are solely responsible for 
compliance with any copyright, patent or trademark restrictions and are referred to the 
copyright, patent or trademark notices appearing in the original sources, all of which are 
hereby incorporated by reference. 
MedDRA®, the Medical Dictionary for Regulatory Activities terminology, is the 
international medical terminology developed under the auspices of the International 
Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH). 
MedDRA® trademark is owned by IFPMA on behalf of ICH. 
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